PLx Pharma Inc a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products, with its lead products VAZALORE 325 mg and VAZALORE 81 mg ,referred to together as VAZALORE, announced that three stock-keeping units of VAZALORE, the first and only U.S. Food and Drug Administration approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.
Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.
“As we continue to execute on our commercial launch plans, we are delighted that Walgreens has committed to carrying all three SKUs of VAZALORE in over 8,000 of its stores throughout the country. Walgreens’ focus on health and wellbeing aligns closely with our mission to bring VAZALORE to the millions of people who can benefit from our unique aspirin therapy,” stated Natasha Giordano, Chief Executive Officer of PLx.
